We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tern Plc | LSE:TERN | London | Ordinary Share | GB00BFPMV798 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -3.85% | 2.50 | 2.40 | 2.60 | 2.60 | 2.50 | 2.60 | 1,705,023 | 09:22:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 66k | -10.45M | -0.0269 | -0.93 | 9.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/2/2021 07:24 | There have been big buyers too , me one of them , | kcowe | |
04/2/2021 07:21 | Cat amongst the pigeons, ducks are in a row. They are cooking on gas! | rhwillcoll | |
04/2/2021 07:21 | I think a third party will take a stake in DA. TERN are reluctant to take this funding now as DA appear to be on the cusp of dramatic growth, so a few weeks following the "event" should see the valuation increase. The new money injected looks to be only short term to tide them over till the investment appears, so my prediction is a DA revaluation event end March. TERN would be foolish to sell its entire stake, so the revaluation event should see the valuation of the DA shareholding soar. Great RNS. | sdavis | |
04/2/2021 07:21 | Aching between the legs eased considerably with that, thanks Al. Who were all the big sellers causing all the worry, think they'll regret selling now ! | upthegardenpath | |
04/2/2021 07:18 | Hope these large sellers feel sick this morning making us all think the worse, nicking £500 pounds or less, this will be double figures today . | wardy333 | |
04/2/2021 07:17 | MCAP of £25m, me thinks we might be undervalued! GLA | gobstopper | |
04/2/2021 07:17 | Sounds like DA is the complete solution for iot security!! Get it sold or ipo’d in the US while huge sums sloshing around. | still waiting | |
04/2/2021 07:17 | Great RNS...well done Al and the BODs. Hope the ridiculous doubters will be quiet hereon in. | goofrob | |
04/2/2021 07:15 | A superb RNS. Excellent in every way. No placings needed, emphasised twice. Well done AS and company. | rhwillcoll | |
04/2/2021 07:15 | Excellent update and categorically rules out near term placement probably until after an exit ! Sellers' from yesterday may not be too happy :-))) | moneymaker6 | |
04/2/2021 07:14 | The two key words are "current needs" these open up the prospects of future fundraising's as before.Happy to provide an RNS translation service to the excitable bunny's. | jonc | |
04/2/2021 07:14 | No placings coming very good news, D/A still not self sufficient but looks to me like third party funding coming there or a takeover. | wardy333 | |
04/2/2021 07:13 | Lol, screw all you “smells like a placing” doom mongers. Thanks Al, perfect timing, great RNS. | maarleck | |
04/2/2021 07:13 | Sounds like an easy sell to the pharma’s, increased data that can reduce their costs. | still waiting | |
04/2/2021 07:12 | nice one ... | kcowe | |
04/2/2021 07:11 | Ramptastic stuff.Good morning rampers.MMS to mark it up then close red as LTHs bail out. | jonc | |
04/2/2021 07:10 | Conclusion no need for any fundraising by TERN!That should shut the prophets of doom up! | dave444 | |
04/2/2021 07:10 | Powered by Eva, a proprietary AI machine developed by Talking Medicines, PatientMetRx combines machine learning and NLP to capture the voice of the patient from millions of conversations taking place over multiple sources including social media, forums and blogs, mapped to a curated database of 130,000 regulated global medicines. It distils what patients are saying online, and what they are feeling, into powerful data insights to provide pharmaceutical companies with a systematic way of measuring patient experience towards medicines. Talking Medicines will sell PatientMetRx on a subscription basis to clients. Delivered on a digital dashboard, PatientMetRx provides pharmaceutical companies with a 'Patient Confidence Score' to benchmark each medicine, offering a systematic way of understanding trending patient confidence in their drug brands. Tracking this Patient Confidence Score enables them to more accurately measure the effectiveness of marketing campaigns, reduce budgets, improve market competitiveness and deliver better health outcomes for patients. | still waiting | |
04/2/2021 07:09 | Sting performance in Q4 2020 and Q1 2021!Plus sufficiently funded for current needs!It goes on to talk about third party future funding for portfolio companies!Which means further revaluations!4 BOOMS in one RNS! | dave444 | |
04/2/2021 07:07 | "I believe that particularly given the strong fourth quarter 2020 business performance of the portfolio companies, that has continued into the current year, we are very well positioned. The Board of Tern believes that the Company's cash resources are sufficient for its current needs, including developing the portfolio and supporting the progress of its portfolio companies, taking into account the expectation of the availability of third-party funding to assist the development of the portfolio companies as appropriate." | dave444 | |
04/2/2021 07:06 | Smells like an exit coming. | still waiting |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions